Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma

NCT00761722 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00761722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00761722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
August 12, 2008
Completion date
April 7, 2016
Enrollment
31 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, leukemia, myelomonocytic, chronic, lymphoma, multiple myeloma, myelodysplastic syndromes